NO893367L - Alfa-underenheten av mac-1 leukocytadhesjons-reseptoren. - Google Patents

Alfa-underenheten av mac-1 leukocytadhesjons-reseptoren.

Info

Publication number
NO893367L
NO893367L NO89893367A NO893367A NO893367L NO 893367 L NO893367 L NO 893367L NO 89893367 A NO89893367 A NO 89893367A NO 893367 A NO893367 A NO 893367A NO 893367 L NO893367 L NO 893367L
Authority
NO
Norway
Prior art keywords
mac
molecules
leukocyte adhesion
adhesion receptor
subunit
Prior art date
Application number
NO89893367A
Other languages
English (en)
Norwegian (no)
Other versions
NO893367D0 (no
Inventor
Timothy Springer
Angel Corbi
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of NO893367D0 publication Critical patent/NO893367D0/no
Publication of NO893367L publication Critical patent/NO893367L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70525ICAM molecules, e.g. CD50, CD54, CD102
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/70553Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO89893367A 1988-08-23 1989-08-22 Alfa-underenheten av mac-1 leukocytadhesjons-reseptoren. NO893367L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23535388A 1988-08-23 1988-08-23
US32123989A 1989-03-09 1989-03-09

Publications (2)

Publication Number Publication Date
NO893367D0 NO893367D0 (no) 1989-08-22
NO893367L true NO893367L (no) 1990-02-26

Family

ID=26928829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89893367A NO893367L (no) 1988-08-23 1989-08-22 Alfa-underenheten av mac-1 leukocytadhesjons-reseptoren.

Country Status (13)

Country Link
US (3) US5849896A (fr)
EP (1) EP0364690A3 (fr)
JP (1) JPH0347077A (fr)
KR (1) KR0185964B1 (fr)
AU (1) AU638937B2 (fr)
CA (1) CA1341293C (fr)
DK (1) DK412489A (fr)
FI (1) FI893917A (fr)
HU (1) HU213014B (fr)
IL (1) IL91370A (fr)
NO (1) NO893367L (fr)
NZ (1) NZ230397A (fr)
PT (1) PT91502B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303692A4 (en) * 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5877275A (en) * 1988-06-28 1999-03-02 The General Hospital Corporation Controlling cellular immune/inflammatory responses with β2 integrins
EP0364690A3 (fr) 1988-08-23 1990-07-18 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leukocyte Mac-1
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
ZA901842B (en) * 1989-03-09 1990-12-28 Boehringer Ingelheim Pharma Use of intercellular adhesion molecules,and their binding ligans in the treatment of asthma
EP0462184A4 (en) * 1989-03-09 1992-01-08 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
EP0468257B1 (fr) * 1990-07-20 1999-09-01 Bayer Corporation Formes multimériques du récepteur du rhinovirus humain
AU674556B2 (en) * 1992-10-09 1997-01-02 Center For Blood Research, Inc., The A subpopulation of MAC-1 molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
JPH09512426A (ja) * 1994-04-26 1997-12-16 ファルマシア・アンド・アップジョン・カンパニー 好中球の接着および移動の遮断に有用なMac−1 I−ドメイン蛋白質
CA2193508A1 (fr) * 1994-07-11 1996-01-25 Eugene D. Thorsett Inhibiteurs de l'adhesion leucocytaire
US5696229A (en) * 1995-03-16 1997-12-09 The University Of Virginia Patent Foundation Polypeptide with laminin cell adhesion and morphogenesis activity
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US7400477B2 (en) 1998-08-24 2008-07-15 Leviton Manufacturing Co., Inc. Method of distribution of a circuit interrupting device with reset lockout and reverse wiring protection
US6210897B1 (en) 1999-05-26 2001-04-03 Leif Andersson Identification of canine leukocyte adhesion deficiency in dogs
EP1267926A2 (fr) 2000-03-17 2003-01-02 Millennium Pharmaceuticals, Inc. Methode d'inhibition de la stenose et de la restenose
WO2002018583A2 (fr) 2000-09-01 2002-03-07 The Center For Blood Research, Inc. Polypeptides modifiés stabilisés dans une conformation souhaitée et procédés de production correspondants
US7372678B2 (en) * 2005-08-24 2008-05-13 Leviton Manufacturing Co., Inc. Circuit interrupting device with automatic test
US7852606B2 (en) * 2005-08-24 2010-12-14 Leviton Manufacturing Company, Inc. Self-testing circuit interrupting device
US7911746B2 (en) * 2006-06-01 2011-03-22 Leviton Manufacturing Co., Inc. GFCI with self-test and remote annunciation capabilities
US8603628B2 (en) * 2007-04-30 2013-12-10 Saint-Gobain Performance Plastics Corporation Turbine blade protective barrier
WO2009097469A1 (fr) * 2008-01-29 2009-08-06 Leviton Manufacturing Co., Inc. Appareil et procédé d'interrupteur de circuit détecteur de défaut à autocontrôle
US9759758B2 (en) 2014-04-25 2017-09-12 Leviton Manufacturing Co., Inc. Ground fault detector

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US5424399A (en) * 1988-06-28 1995-06-13 The Children's Medical Center Corporation Human CR3α/β heterodimers
EP0364690A3 (fr) 1988-08-23 1990-07-18 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leukocyte Mac-1

Also Published As

Publication number Publication date
AU4014489A (en) 1990-03-01
FI893917A (fi) 1990-02-24
EP0364690A3 (fr) 1990-07-18
FI893917A0 (fi) 1989-08-21
US20020022595A1 (en) 2002-02-21
US5849896A (en) 1998-12-15
CA1341293C (fr) 2001-09-18
PT91502A (pt) 1990-03-08
HU213014B (en) 1997-01-28
KR0185964B1 (ko) 1999-05-01
IL91370A (en) 1995-07-31
PT91502B (pt) 1995-05-04
IL91370A0 (en) 1990-04-29
HUT54207A (en) 1991-01-28
DK412489D0 (da) 1989-08-22
US6683158B2 (en) 2004-01-27
EP0364690A2 (fr) 1990-04-25
KR900002797A (ko) 1990-03-23
DK412489A (da) 1990-02-24
NZ230397A (en) 1997-07-27
US20030013850A1 (en) 2003-01-16
AU638937B2 (en) 1993-07-15
JPH0347077A (ja) 1991-02-28
NO893367D0 (no) 1989-08-22

Similar Documents

Publication Publication Date Title
NO893367L (no) Alfa-underenheten av mac-1 leukocytadhesjons-reseptoren.
NO893366L (no) Alfa-underenheten til lfa-1 leukocytadhesjons-reseptoren.
ES2102367T3 (es) Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
DE69333109D1 (de) Therapeutische nukleoside
ES2124373T3 (es) Procedimiento para la preparacion de derivados del acido n-acil-n,n',n'-etilendiamintriacetico.
TR200003461T2 (tr) Adenosin A3 Alıcı Modülatörleri
ES2058083T3 (es) Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo.
ATE61357T1 (de) Substituierte phenylsulfonamide.
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
ES2117123T3 (es) Derivados de aminocetilmercaptoacetilamida utilizados como inhibidores de la encefalinasa y del enzima de conversion de angiotensina.
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
ES2080800T3 (es) Polipeptidos y analogos de polipeptidos con actividad inhibitoria frente a la elastasa humana.
ATE306549T1 (de) C-c ckr-1, ein c-c chemokin rezeptor
ES2109658T3 (es) Determinacion de motivos peptidicos en moleculas del mhc.
DK472887A (da) Imidazolylguanidinderivater, fremgangsmaade til fremstilling deraf og laegemidler, der indeholder disse forbindelser
IT1207498B (it) Procedimento per la preparazione di composizioni plasto-elastomeriche poliolefiniche, mediante vulcanizzazione dinamica.
NO892125D0 (no) Kombinasjon av angiotensin-omvandlende-enzymhemmere med kaliumkanal-modulatorer samt deres anvendelse i legemidler.
NO995693D0 (no) Guanidinylering av reagenser
GB1320759A (en) Apparatus for sewage treatment
DK163566C (da) Anvendelse af hygromycin og epihygromycin til fremstilling af et medikament til behandling af svinedysenteri
FR2456095A2 (fr) Preparation de benzoxazolone
ATE25247T1 (de) 4-amino-3-imidazolin-2-on und (2-methoxy-2-imino- ethyl)-harnstoff, ihre herstellung und verwendung.
DE69532611D1 (de) Mittel zur behandlung von autoimmunkrankheiten
SE9603726D0 (sv) Novel compounds
ES2169750T3 (es) Utilizacion de ribonucleasa seminal como compuesto antimetastatica.